News headlines about Lexicon Pharmaceuticals (NASDAQ:LXRX) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lexicon Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.6587900742747 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern’s scoring:

A number of research firms have recently issued reports on LXRX. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. BidaskClub raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, June 14th. Zacks Investment Research lowered Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 5th. Cowen and Company reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Finally, Wedbush reaffirmed an “ourperform” rating and set a $39.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday, August 7th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $27.00.

Shares of Lexicon Pharmaceuticals (NASDAQ LXRX) traded up 0.34% on Monday, reaching $14.78. The company had a trading volume of 151,335 shares. The company’s market capitalization is $1.56 billion. The stock has a 50 day moving average price of $15.03 and a 200-day moving average price of $15.40. Lexicon Pharmaceuticals has a 12 month low of $13.41 and a 12 month high of $19.62.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The firm had revenue of $12 million for the quarter, compared to analysts’ expectations of $18.34 million. During the same period last year, the firm earned ($0.37) EPS. The firm’s revenue was down 40.3% compared to the same quarter last year. Analysts forecast that Lexicon Pharmaceuticals will post ($1.45) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/11/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-lexicon-pharmaceuticals-lxrx-stock-price.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Insider Buying and Selling by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Stock Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.